AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.

Create a link to this page

Copy and paste this link tag into your Web page or blog:

<a href="http://www.accessmylibrary.com/coms2/summary_0286-4150483_ITM" title="Facts and information about FDA approves lamotrigine for bipolar disorder. (Business Notes).(Lamictal)(Brief Article)">FDA approves lamotrigine for bipolar disorder. (Business Notes).(Lamictal)(Brief Article)</a>

Close Set up an RSS feed that alerts you when new articles from Mental Health Weekly are available.

Frequently asked questions about RSS feeds

FDA approves lamotrigine for bipolar disorder. (Business Notes).(Lamictal)(Brief Article)

Mental Health Weekly

| June 30, 2003 | This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)Copyright

The U.S. Food and Drug Administration (FDA) has approved lamotrigine (Lamictal) tablets for the long-term maintenance treatment of bipolar I disorder, drug maker GlaxoSmithKline announced. The FDA specifically approved lamotrigine for the maintenance treatment of adults with bipolar I disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard therapy. The last long-term treatment for bipolar disorder approved by the FDA was Lithium for maintenance of bipolar I disorder, according to GlaxoSmithKline.

The FDA approved lamotrigine based on the…

View articles courtesy of your local library

Related articles from newspapers, magazines, journals, and more


Lamictal.(New & Approved)(lamotrigine from GlaxoSmithKline)(Brief Article): Magazine article from: Family Practice News Mechcatie, Elizabeth August 15, 2003 700+ words
...treatment of bipolar I disorder to delay the time to occurrence of mood episodes (depression, mania, hypomania, mixed episodes) in patients treated for acute mood episodes with standard therapy. The third drug approved for a bipolar indication...


Divalproex did not differ from placebo or lithium in preventing recurrence of...: Magazine article from: Evidence-Based Mental Health CL, Bowden JR, Calabrese SL, McElroy February 1, 2001 700+ words
...with placebo and lithium in preventing recurrence of new mood episodes? Design 1 year randomised (allocation concealed...efficacious than placebo or lithium in preventing recurrence of new mood episodes. (*.) See glossary. (+.) Information provided by...


Recurring mood episodes twice as great in bipolar women who discontinue...: Newspaper article from: The Brown University Child and Adolescent Psychopharmacology Update February 1, 2008 700+ words
...weeks compared with >41 weeks in women who continued treatment. The study was carried out to estimate the risk of mood episodes recurring in pregnant women with bipolar disorder who continued taking mood stabilizers versus those who discontinued such...


Lamotrigine approved for maintenance in BD.(News Updates bipolar...: Magazine article from: Brown University Psychopharmacology Update August 1, 2003 700+ words
The FDA recently approved lamotrigine (Lamictal) for long-term maintenance treatment...adults, specifically to delay the onset of mood episodes in patients treated for acute mood episodes. Lamotrigine is the first medication approved...


Lamotrigine approved for maintenance in BD. (News Updates).(bipolar...: Newspaper article from: The Brown University Geriatric Psychopharmacology Update August 1, 2003 700+ words
The FDA recently approved lamotrigine (Lamictal) for long-term maintenance treatment...specifically to delay the onset of recurrent mood episodes in patients treated for acute mood episodes. Lamotrigine is the first medication approved...


Lamotrigine approval for bipolar I hailed as a first: like 'mirror image of...: Magazine article from: Clinical Psychiatry News Mechcatie, Elizabeth August 1, 2003 700+ words
...The Food and Drug Administration approved lamotrigine (Lamictal), an antiepileptic marketed...to delay the time to occurrence of mood episodes (depression, mania, hypomania...episodes) in patients treated for acute mood episodes with standard therapy." This is...


First effectiveness study tests treatments for refractory bipolar...: Magazine article from: Brown University Psychopharmacology Update August 1, 2006 700+ words
...antipsychotic; and inositol, a glucose isomer sold in health-food stores. The Food and Drug Administration has approved lamotrigine as maintenance monotherapy for bipolar I disorder and risperidone for acute mania. Nierenberg said inositol...


NDA submitted for lamotrigine for depressive episodes in BD. (News...: Magazine article from: Brown University Psychopharmacology Update November 1, 2002 700+ words
...Lamictal) for the long-term delay of relapse or recurrence of depressive episodes in bipolar I disorder (BD). If approved, lamotrigine would be the first drug for this indication. "Many effective treatments are available for the acute mania associated...


Long-Term Treatment With Lamictal Is Not Associated With Clinically Relevant...: Press release article from: PR Newswire May 5, 2004 700+ words
...to delay the time to occurrence of mood episodes (depression, mania, hypomania...episodes) in patients treated for acute mood episodes with standard therapy. The effectiveness...Lamictal in the acute treatment of mood episodes has not been established. BACKGROUND...


New Expanded Indication For Lamictal(R) Offers Additional Treatment Options For...: Press release article from: PR Newswire January 15, 2004 700+ words
...to delay the time to occurrence of mood episodes (depression, mania, hypomania...episodes) in patients treated for acute mood episodes with standard therapy. "This FDA...to delay the time to occurrence of mood episodes (depression, mania, hypomania...

For more facts and information, see all results

The AccessMyLibrary advertising network includes: